


## People with IgA Nephropathy may be eligible for the enVISION research study.



The enVISION study is evaluating the safety and effectiveness of an investigational drug called VIS649 for Immunoglobulin A Nephropathy (IgAN). Around 144 people in about 15 countries will participate in this research study.

You may qualify to participate if you:

- Are at least 18 years of age
- Have been diagnosed with IgAN (confirmed by a kidney biopsy)
- Have been taking a stable, maximally tolerated dose of certain blood pressure medications for the last 3 months (or are unable to tolerate these medications)
- Have not taken systemic corticosteroids or medications that suppress your body's immune system in the last 16 weeks
- Are willing and able to use study-provided supplies to collect your urine for 24 hours and then return it to the study nurse

Other criteria will be reviewed at the first study visit to determine if you are able to participate in the study.

The enVISION study lasts about 17 months and requires about 18 visits to a local study clinic for study-related tests and procedures. All study-related office visits, medical procedures, laboratory tests, and study intervention are provided at no cost to qualified participants. At the end of study completion, you may be able to participate in an extension study in which all participants will receive VIS649.

To learn more about the enVISION study, please visit <https://enVISIONIgANstudy.com> or call us at (713)907-6054.